News

Philadelphia—The astigmatism induced by conductive keratoplasty (CK) can be minimized by obtaining better centration of the corneal template mark around the pupil.

New Orleans—Incorporating higher-order aberrations (HOAs) into LASIK treatment performed with aspherically optimized profiles using the MEL80 excimer laser (Carl Zeiss Meditec) increases treatment benefit without compromising refractive accuracy, said Dan Z. Reinstein, MD, MA (Cantab), FRCSC, at the ISRS subspecialty day meeting.

New Orleans—Joshua D. Stein, MD, MS, of Manhattan Eye, Ear, and Throat Hospital (MEETH), was named the winner of the second annual Ophthalmology Times Resident Writer's Award Program. The program was presented and sponsored by Advanced Medical Optics (AMO).

Joshua D. Stein, MD, MS, received his Bachelor of Arts degree from Wesleyan University with a double major in neuroscience and behavior and psychology. He then attended the Center for the Evaluative Clinical Sciences at Dartmouth Medical School and received a Master of Science degree. From there, he went on to Jefferson Medical College and obtained his Doctor of Medicine degree. Dr. Stein is currently a chief resident in ophthalmology in the New York University School of Medicine/Manhattan Eye, Ear and Throat Hospital (MEETH) residency program, and will pursue a fellowship in glaucoma at Duke University next year. Dr. Stein is a prolific researcher and investigator, having published numerous articles in peer-reviewed journals and presented his research at many national and international meetings.

Editor's Note: Joshua D. Stein, MD, MS, of New York University School of Medicine and Manhattan Eye, Ear, and Throat Hospital (MEETH), was named the winner of the second annual Ophthalmology Times Resident Writer's Award Program—presented during the American Academy of Ophthalmology annual meeting in New Orleans. Dr. Stein's winning submission is featured here. He was nominated by Laurence T.D. Sperber, MD, the residency program director and clinical associate professor of ophthalmology at New York University School of Medicine and director of the Cornea Service at MEETH in New York.

Fort Worth, TX—Alcon Laboratories Inc. has submitted the third and final reviewable unit of its new drug application (NDA) for anecortave acetate for depot suspension (Retaane) to the FDA.

Rochester, NY—Bayer HealthCare LLC's Biological Products Division has granted Bausch & Lomb (B&L) an exclusive worldwide license to its Plasmin technology for use in developing novel therapies for ocular conditions.

Vienna, Austria—In an unprecedented event, the Association of International Glaucoma Societies (AIGS) is hosting the World Glaucoma Congress in Vienna, Austria. Organizers believe the meeting, which runs July 6 to 9, will attract about 2,000 general ophthalmologists, glaucoma specialists, and industry representatives to study a disease that is debilitating to more than 100 million people worldwide.

A waterfall may just be a waterfall for many passers-by, but in the eyes of David A. Snyder, MD, the cascading water may be an intricate part of a photograph waiting to be captured.

The Accreditation Council forContinuing Medical Education (ACCME) has awarded theAmerican Academy of Ophthalmology' (AAO) CME program Accreditation with Commendation, a distinction awarded to only 8% of all accredited CME providers, and one that is seldom achieved by a medical specialty society.

New Orleans—Travoprost 0.004% (Travatan, Alcon Laboratories) lowers IOP by both increasing outflow facility and improving uveoscleral outflow, according to the results of a clinical study designed to investigate the mechanism of action of travoprost.

New Orleans—Twice-daily administration of a fixed-combination product containing brimonidine 0.2% plus timolol 0.5% (Combigan, Allergan Inc.) safely and effectively lowers IOP, according to the pooled results of two 12-month, randomized, double-masked, phase III studies.

Timolol maleate ophthalmic solution 0.5% (Istalol, ISTA Pharmaceuticals), available in a new, once-a-day formulation, is as effective as a standard 0.5% timolol maleate ophthalmic solution administered twice daily to treat elevated IOP in ocular hypertension and open-angle glaucoma.

Norristown, PA—Transciliary filtration (TCF) offers an alternative for safe and effective IOP lowering in phakic primary open-angle glaucoma but with many advantages relative to trabeculectomy.

New Orleans—Results of a prospective, randomized, double-masked study demonstrate a fixed combination of travoprost 0.004% and timolol 0.5% (Extravan, Alcon Laboratories) administered once daily is safe, well-tolerated, and offers better IOP lowering than monotherapy using either of its components, said Howard S. Barnebey, MD.

Uppsala, Sweden—Adjunctive latanoprost (Xalatan, Pfizer) therapy for open-angle glaucoma is safe and effective, based on the results of a 5-year assessment of the drug. The mean decrease in IOP was 25% of the baseline IOP and this was sustained without any treatment change in 70% of eyes.

New Orleans—Patient adherence to prostaglandin analogue or prostamide therapy for glaucoma is high but not perfect. There are still opportunities to improve adherence to therapy with these drugs, according to Jacob Wilensky, MD.

New Orleans—The ExPRESS miniature glaucoma shunt (Optonol Ltd., Neve Ilan, Israel; marketed by CIBA Vision, Duluth, GA), originally intended to be placed through the limbus and under a conjunctival flap, produced significant IOP lowering yet an unacceptable high rate of complications. So researchers are now investigating placement of the device under a scleral flap, according to Marlene R. Moster, MD.

New Orleans—Bleb needling may be a good approach for early bleb failure if medication, digital massage, and suture lysis or removal are not effective. In the case of late bleb failure, YAG laser lysis of the sclerotomy, bleb needling, and bleb revision are favored, according to glaucoma specialist Jon M. Ruderman, MD.

New Orleans—One of the most complex aspects of glaucoma management is establishing a safe level of IOP, below which damage will not occur. But should this level be determined by a number or a percentage?

New Orleans—One of the most complex aspects of glaucoma management is establishing a safe level of IOP, below which damage will not occur. But should this level be determined by a number or a percentage?

San Francisco—A drug commonly prescribed for older men suffering from prostate enlargement seems to cause a "floppy iris" that increases the risk of complications during cataract surgery.

Vienna, Austria—Until recently, there was little, if any, communication among regional and national glaucoma societies that might reveal greater insights or solutions for the management and treatment of the disease.

Recently, a chairperson of a prominent department of ophthalmology, and someone I admire tremendously, reminded me of a major issue facing our specialty. Academic ophthalmology is facing a shortage of department chairpersons. Approximately 25 departments are currently without a permanent chairperson. On average, after 2 years of search committee activity, 50% of these positions remain unfilled.

As the practice of ophthalmology continues to evolve, it is important for physicians to remain up to date with the latest advances and discoveries in ways to preserve and protect their patients' vision.

Baltimore—Innovative pharmaceutical delivery systems are showing promise for their potential to provide safe and effective "site-directed" therapy for retinal diseases, said Eugene de Juan Jr., MD, in the Ronald G. Michels Memorial Lecture at the Current Concepts of Ophthalmology meeting.

New Orleans—Cytoskeletal agents, which increase outflow facility in the trabecular meshwork, are one of the drug classes that could expand the pharmaceutical options available to reduce IOP, said Carl B. Camras, MD, professor, chairman, and director of the glaucoma service, department of ophthalmology, University of Nebraska Medical Center, Omaha.

Santa Clara, CA—CustomVue LASIK (VISX) performed with the WaveScan system and the STAR S4 excimer laser has become the first wavefront-guided laser treatment approved by the FDA for correction of hyperopia and hyperopic astigmatism.